Re proposition to Stanley Remedies

Question: Write a letter to all managers regardingRe-proposition to Stanley Remedies for genetically modified medicine. Answer: To: All Managers From: Trevor Martin CEO of ABACAS Management Consultant Date: 24/05/16 Subject: Re-proposition to Stanley Remedies for genetically modified medicine After a prolong study of the potential market I have determine to Re-propose Australian pharmaceutical company Stanley Remedies to start their venture for genetically modified medicine for the market of Unite Kingdom. The first proposal was offered one year before regarding the aforesaid issue. They replied on that subject matter after six month of the receiving of the proposal. The client company made a sceptical analysis of the whole subject matter and find it difficult to implement. We received a formal rejection of the given proposal from their end in the month of December 2016. According to their proposal the project will not offer any opportunity of immediate prospect for the firm that realisation is propelling the company to abandon the project. The Australian counterpart of the company Mr. Andy Moor has described his stand regarding the issue. He describe the proposal is indicating towards a long term outcome rather any immediate return. An enterprise should not embark towards any uncertain direction that will not offer any immediate outcome. I do recognise the concern and admit to incorporate their view to constitute the re- proposition. I must appreciate the view of Mr. Ted Hume the G.M. of our client company Stanley Remedies in this occasion. Mr. Hume is critical regarding the high investment for the long term benefit, I do admit his concern but he also describe the proposal is indicating towards the horizon. Let the issue get analysed from this angle. The subject of our proposition can get defined as New Product Development. As it is known that in NPD strategy latent market demand and clients ability occupy important position. The demand for the proposed product has already been realised through the market research. There are several terminal illnesses such as cardiac problem and cancer are directly influenced by genetic issue. The live saving drug industry in all over world are introducing large amount of fund to develop the remedy for these cardinal threat of humanity. As we know our client has already confirm its position in the pharmaceutical industry of its own country Australia. This proposal is offering them to penetrate British market with the new product. In our last meeting held on 23.05.16 we have develop a consensus that the process of re-proposition is leading us towards a desirable direction. The visualisation we have made from our clients end is an imperative for any NPD endeavour. United Kingdom is the country known for its public health system National Health Service or NHS is a unique public health system that attracts interest of the patient from different part of the world. According to the statistics in the year 2013 fifty two thousand foreign patient has been treated in United Kingdom. This information validate our clime that in this country a base of high quality treatment already exist what an Australian company can explore by offering some high quality medicine that the market will accept. In our last meeting some prominent member of pour team expressed their views and concern regarding the subject area. The marketing head Mr. Felix expressed his concern regarding our expertise in this type of enterprise. As we know as a management consultant we do provide relevant support to the business enterprises, this endeavour is a market development activity from our end too. Our Australian client has already confirmed its prominent position in the indigenous local market of the country this particular status of any company induces them to opt for overseas market development. On the basis of the entire angle I must conceder this is the propitious atmosphere to embark beyond the familiar periphery. I do invite your suggestion in this regard. Reference: Binsardi, A., Ekwulugo, F. (2003). International marketing of British education: research on the students' perception and the UK market penetration.Marketing Intelligence Planning,21(5), 318-327. Carlile, P. R. (2002). A pragmatic view of knowledge and boundaries: Boundary objects in new product development.Organization science,13(4), 442-455. Ham, C., York, N., Sutch, S., Shaw, R. (2003). Hospital bed utilisation in the NHS, Kaiser Permanente, and the US Medicare programme: analysis of routine data.Bmj,327(7426), 1257. Leonardà ¢Ã¢â€š ¬Ã‚ Barton, D. (1992). Core capabilities and core rigidities: A paradox in managing new product development.Strategic management journal,13(S1), 111-125. Rust, R. T., Lemon, K. N., Zeithaml, V. A. (2004). Return on marketing: Using customer equity to focus marketing strategy.Journal of marketing,68(1), 109-127.